Phase I Study of Progerinin in Healthy Volunteers

Exclusion criteria

• . The subject has a history of severe allergic or anaphylactic reactions.
• . The subject has a known allergy or hypersensitivity to any component of the formulation.
• . The subject has a medical history or current evidence of any clinically significant (as determined by the investigator) cardiac, endocrine (including diabetes), hematologic, hepatobiliary (abnormal 12lanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], gamma-glutamyl transpeptidase \[GGT\], or total bilirubin), immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, or renal condition, or other major disease.
• . The subject has a history of any malignant disease.
• . The subject has a history of more than one herpes zoster episode or multimetameric herpes zoster.
• . The subject has a history of an opportunistic infection (e.g. cytomegalovirus, pneumocystis carinii, aspergillosis, clostridium difficile).
• . The subject has a history of or ongoing chronic or recurrent infectious disease (e.g. infected indwelling prosthesis, osteomyelitis, chronic sinusitis).
• . The subject has had major trauma or surgery in the 2 months before screening or at any time between screening and check-in.

Incidence of abnormal physical examination findings

Timeframe: At baseline, 96 hours after the last study drug administration, and on Day 7 after the last study drug administration